Evidence map›Paper›PMID 32585158›Full record

ArticleThe American journal of pathology2020

Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling.

Filip Roudnicky, Cedric Poyet, Lorenz Buser, Karim Saba, Peter Wild, Vivianne I Otto, Michael Detmar

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Promise of spatially resolved omics for tumor research.Journal of pharmaceutical analysis · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Spatially resolved transcriptomics and its applications in cancer.Current opinion in genetics & development · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Filip RoudnickyInstitute of Pharmaceutical Sciences, ETH Zurich, Zürich, Switzerland.
Cedric PoyetDepartment of Urology, University Hospital Zurich, Zürich, Switzerland.
Lorenz BuserInstitute of Pathology and Molecular Pathology, University Hospital Zurich, Zürich, Switzerland.
Karim SabaDepartment of Urology, University Hospital Zurich, Zürich, Switzerland.
Peter WildInstitute of Pathology and Molecular Pathology, University Hospital Zurich, Zürich, Switzerland.
Vivianne I OttoInstitute of Pharmaceutical Sciences, ETH Zurich, Zürich, Switzerland.
Michael DetmarInstitute of Pharmaceutical Sciences, ETH Zurich, Zürich, Switzerland. Electronic address: michael.detmar@pharma.ethz.ch.
University Hospital of Zurich · CHETH Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated blood vessels differ from normal vessels and play key roles in tumor progression. We aimed to identify biomolecules that are expressed differentially in human bladder cancer-associated blood vessels to find novel biomarkers and mechanisms involved in tumor-associated angiogenesis. The transcriptome of tumor blood vasculature from human invasive bladder carcinoma (I-BLCA) and normal bladder tissue vasculature was compared using differential expression and unsupervised hierarchical clustering analyses. Pathway analysis identified up-regulation of genes involved in the proliferation, cell cycle, angiogenesis, inflammation, and transforming growth factor-β signaling in tumor blood vasculature. A common consensus gene expression signature was identified between bladder cancer tumor blood vasculature with tumor blood vasculature of other solid cancers, which correlated with the overall survival of patients with several of the solid cancers investigated in The Cancer Genome Atlas data set. In bladder tumor blood vasculature, the secreted factor angiopoietin-like protein 2 (ANGPTL2), was confirmed to be up-regulated by quantitative RT-PCR and immunohistochemical staining. The up-regulation of ANGPTL2 in plasma was also observed in non-invasive bladder carcinoma and I-BLCA. We semiquantitatively analyzed expression of ANGPTL2 in tissue microarrays from I-BLCA and surprisingly found an opposite correlation between staining intensity and progression-free survival. Our results indicate that ANGPTL2 might serve as a potential biomarker to predict progression-free survival in I-BLCA.

Indexed as

Angiopoietin-Like Protein 2Angiopoietin-like ProteinsBiomarkers, TumorGene Expression ProfilingHumansLaser Capture MicrodissectionNeovascularization, PathologicTranscriptomeUrinary Bladder NeoplasmsAngiopoietin-Like Protein 2Angiopoietin-like ProteinsANGPTL2 protein, humanBiomarkers, Tumor

Identifiers

PMID32585158
PMCPMC12179517
OpenAlexW3037262423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.